Ibuzatrelvir PF-07817883 CAS 2755812-39-4 Molecular Weight 489.49 Formula C21H30F3N5O5 Ibuzatrelvir (development code PF-07817883) is an experimental antiviral drug being developed by Pfizer for the treatment of COVID-19.[1] It is a second-generation improvement over nirmatrelvir which has a similar chemical structure.[2] One of the disadvantages of nirmatrelvir is that it has low metabolic stability and must be given in combination with ritonavir (as Paxlovid) to limit its metabolic degradation in the body.[3] Ibuzatrelvir … Continue reading Ibuzatrelvir